MedTrace Logo

Intrathecal Bupivacaine-fentanyl and Bupivacaine-dexmedetomidine for Elective Low Segment Caesarean Section

NCT04095013 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-09-19

No results posted yet for this study

Summary

the primary objective of the study is to compare the onset and recovery times of sensory and motor blockade of the two study drugs intrathecally with low dose bupivacaine The secondary objectives of the study are to observe hemodynamics, side effects profile, and duration of postoperative analgesia

Conditions

  • Cesarean Section Complications

Interventions

DRUG

Bupivacaine, fentanyl

Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,

DRUG

Bupivacaine, dexmedetomidine

Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms

Sponsors & Collaborators

  • Dow University of Health Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-06-15
Completion
2019-07-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04095013 on ClinicalTrials.gov